Krystal Biotech (KRYS)

• Market cap: $4.74B
• 1 day: 2.49%
• 5 days: 1.40%
• 1 month: -7.45%
• 3 months: -10.50%
• 6 months: -3.73%
• Year to date: 31.91%
• 1 year: 45.94%
• 5 years: 187.81%
• 10 years: 1,449.15%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Employees: 229

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 18

34% more call options, than puts

Call options by funds: $89.7M | Put options by funds: $67.2M

18% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 88

15% more funds holding

Funds holding: 242 [Q2] → 278 (+36) [Q3]

5% less capital invested

Capital invested by funds: $5.36B [Q2] → $5.1B (-$266M) [Q3]

4.8% less ownership

Funds ownership: 102.25% [Q2] → 97.45% (-4.8%) [Q3]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $206 25% upside
• Avg. target: $213 29% upside
• High target: $221 34% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target	29% upside $212	Buy Maintained	18 Dec 2024
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 80 / 385 met price target	34% upside $221	Buy Reiterated	18 Dec 2024
Citigroup Yigal Nochomovitz 28% 1-year accuracy 13 / 46 met price target	25% upside $206	Neutral Maintained	5 Nov 2024